Overview
Semaglutide is the first GLP-1 with an FDA-approved CV indication for non-diabetic patients. SELECT trial: 20% MACE reduction in non-diabetic adults with overweight/obesity + CVD.
Related guides
- 503A vs 503B Compounding Pharmacies Explained
- Semaglutide Cost Guide — Brand vs Compounded Pricing
- Semaglutide Side Effects — What Patients Report
- Semaglutide Dosing Schedule
- BMI Eligibility for Semaglutide Weight Management
- Compounded vs Brand-Name Semaglutide
- Semaglutide Insurance Coverage
- How Semaglutide Works — Mechanism Explained